PennyStocks101 Reports 3 TOP Stocks to Watch Closely: Biolinerx Ltd., Vical Inc., and Pluristem Therapeutics

Beverly Hills, CA -- (SBWIRE) -- 01/15/2013 -- http://www.PennyStocks101.com - The US leader in microcap breakouts, offers a high quality stocks alert newsletter to investors looking for the best breakout stocks around. PennyStocks101 reports 3 penny stocks to keep an eye on for a possible bounce or more gains: BLRX, VICL, and PSTI

The market dipped even lower on Tuesday as investors show concern over the U.S.'s borrowing limit increasing. The Dow Jones industrial average fell 11 points to 13,495 as of 12:03 p.m. EST. The Standard and Poor's 500 dropped two points to 1,468, the Nasdaq composite index fell 14 points to 3,102.

1. Biolinerx Ltd. (NASDAQ:BLRX) - Bioline RX Ltd. is a biopharmaceutical development company.

2. Vical Inc. (NASDAQ:VICL) - Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

3. Pluristem Therapeutics (NASDAQ:PSTI) - PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.

Pennystocks101.com educates and shows investors the inner workings of the volatile world of penny stocks by scouring the markets for the hottest penny stocks that look poised to break out. Discover the next hidden company to profit. Sign up for the free newsletter to receive the next big report soon. Join at: http://www.PennyStocks101.com

Sign Up at - http://www.PennyStocks101.com for more ideas to put on your radar.

Disclosure
Pennystocks101.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. This press release may contain several forward looking statements. Please read our report and visit our website for complete risks and disclosures.